WASHINGTON — The FDA accepted a novel indication for esketamine (Spravato): predominant despair with suicidal ideation or habits, drugmaker Janssen announced Monday. Beforehand, the drug…
WASHINGTON — The FDA accepted a novel indication for esketamine (Spravato): predominant despair with suicidal ideation or habits, drugmaker Janssen announced Monday. Beforehand, the drug…